US Patent 10220023 Dosing regimen for a selective S1P
Patent 10220023 was granted and assigned to Actelion on March, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 10 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+175 characters)
Article
Patent abstract
The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.
Edits on 2 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Andreas Krause0
Jasper Dingemanse0
Matthias Hoch0
Edits on 14 Jun, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
102200230
Date of Patent
March 5, 2019
0Patent Application Number
155349290
Date Filed
December 10, 2015
0Patent Citations Received
Patent Primary Examiner
Edits on 23 Sep, 2022
Golden AI
Infobox
Patent Citations Received
Edits on 12 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 25 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10220023 Dosing regimen for a selective S1P
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10220023
Date of patent
March 5, 2019
Patent application number
15534929
Date Filed
December 10, 2015
Patent primary examiner
Find more entities like US Patent 10220023 Dosing regimen for a selective S1P
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
